Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study

Fig. 3

Transcriptomic analysis of baseline tumor samples in arm B. Differential expression analysis (a) and GSEA (b) in tumor samples from responders (n = 2) and non-responders (n = 11). c Receiver operating characteristic plots of the predictive values of TYROBP and PILRA expression for response to neoadjuvant treatment. Patients with high TYROBP expression presented with better OS (d) and EFS (e). f Boxplot showing immunescore in baseline tumor samples from responders versus non-responders. g Increasing CD8 + T cells in baseline tumor samples from responders. h Increasing T cell effectors’ expression in baseline tumor samples from responders. Boxplots showing fraction of TCR reads (i) and unique TCR CDR3 (j) in baseline tumor samples from responders versus non-responders. Two-sided Wilcoxon rank sum test was used for comparison in figure (f–j). *P < 0.05; **P < 0.01; ***P < 0.001. ns, not significant

Back to article page